SEOM clinical guidelines for the treatment of renal cell carcinoma

DSpace/Manakin Repository

SEOM clinical guidelines for the treatment of renal cell carcinoma

Show simple item record

dc.contributor.author Bellmunt, J. en_US
dc.contributor.author Puente, J. en_US
dc.contributor.author Garcia de Muro, J. en_US
dc.contributor.author Lainez, N. en_US
dc.contributor.author Rodríguez, C. en_US
dc.contributor.author Duran, I. en_US
dc.date.accessioned 2014-12-02T21:28:55Z
dc.date.issued 2014 en_US
dc.identifier.citation Bellmunt, J., J. Puente, J. Garcia de Muro, N. Lainez, C. Rodríguez, and I. Duran. 2014. “SEOM clinical guidelines for the treatment of renal cell carcinoma.” Clinical & Translational Oncology 16 (12): 1043-1050. doi:10.1007/s12094-014-1219-1. http://dx.doi.org/10.1007/s12094-014-1219-1. en
dc.identifier.issn 1699-048X en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454797
dc.description.abstract The purpose of this article was to provide updated recommendations for the diagnosis and treatment of renal cell carcinoma. Pathological confirmation is mandatory before treatment with ablative or focal therapies before any type of systemic therapy. Renal cell cancer should be staged according to the TNM classification system. A laparoscopic nephron-sparing surgery should be the approach for tumors <4 cm if technically feasible. Otherwise, radical (or partial in selected cases) nephrectomy is the treatment of choice, with lymph node dissection only performed in patients with clinically detected lymph node involvement. Some retrospective evidence for a cytoreductive nephrectomy in the postimmunotherapy era suggests a benefit in patients with good or intermediate risk or for patients with a symptomatic primary lesion. Adjuvant treatment with chemotherapy or with targeted agents is not recommended and studies are ongoing today. Patients with metastatic disease should be staged by computed tomography scans of the chest, abdomen and pelvis. The efficacy of sunitinib, bevacizumab plus interferon-α, and pazopanib is well established in patients with good and intermediate risk as well for temsirolimus in poor-risk patients. These four agents are considered standard of care in first-line treatment. Sorafenib, axitinib and everolimus are standard of care in second line in different settings based on their benefit in PFS. Besides some benefit described for IL-2 in highly selected patients in first line, there is a promising and emerging role for the new immunotherapeutic approaches in metastatic renal cell carcinoma. en
dc.language.iso en_US en
dc.publisher Springer Milan en
dc.relation.isversionof doi:10.1007/s12094-014-1219-1 en
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239764/pdf/ en
dash.license LAA en_US
dc.subject Renal cell carcinoma en
dc.subject SEOM en
dc.subject Guidelines en
dc.title SEOM clinical guidelines for the treatment of renal cell carcinoma en
dc.type Journal Article en_US
dc.description.version Version of Record en
dc.relation.journal Clinical & Translational Oncology en
dc.date.available 2014-12-02T21:28:55Z

Files in this item

Files Size Format View
4239764.pdf 221.1Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters